Drug Profile
Research programme: infertility therapeutics - Merck Serono/Syntonix
Alternative Names: Follicle-stimulating hormone-Fc fusion protein; FSH-Fc; FSH:Fc SynFusion™ drugs; FSH:Fc SynFusion™ productsLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Syntonix Pharmaceuticals
- Developer EMD Serono; Merck Serono; Syntonix Pharmaceuticals
- Class Follicle stimulating hormones; Pituitary gonadotropins; Recombinant fusion proteins
- Mechanism of Action Ovarian follicle stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Female infertility
Most Recent Events
- 01 Feb 2007 Syntonix Pharmaceuticals has been acquired by Biogen Idec
- 08 Jan 2007 Serono is now called Merck Serono
- 05 Jan 2007 Serono has been acquired by Merck KGaA